Myeloproliferative Disorders: Introduction
- Myeloproliferative disorders are a group of medical conditions that cause abnormal increase in the production of blood cells such as red blood cells, white blood cells, and platelets
- There are different types of myeloproliferative disorders, and this depends upon the type of blood cells being overproduced in the body.
- The myeloproliferative disorder usually affects one type of blood cells; however sometimes, it may affect two or more blood cells
- Common symptoms of myeloproliferative disorders are fatigue, fever, weight loss, bone pain, sweating in nights, and sometimes they, may cause frequent infections
- Treatment of myeloproliferative disorders includes prescription medicines such as hydroxyurea, Janus Kinase 2 Inhibitors (JAK 2 Inhibitors), and low dose aspirin. The other treatment comprises blood treatments such as phlebotomy and blood transfusions and stem cell transplantation.
Myeloproliferative Disorders Market: Key Drivers
- Scope of advancements in currently used drugs for myeloproliferative disorders and large unmet demand for therapeutics of myeloproliferative disorders are major factors that are estimated to drive the myeloproliferative disorders market.
- Drugs currently being used for myeloproliferative disorders have not displayed considerable efficacy for prevention of hematological progression, reduction of cardiovascular complications, normalization of life span, and improved quality of life for patients with myeloproliferative disorders
- Thus, in spite of treatment, patients of myeloproliferative disorders do not display significant improvement in quality of life, and may not attain a normal lifespan
- Such strong unmet needs provide lucrative opportunities for players to develop first-in-class therapies for myeloproliferative disorders
Chemotherapy Segment to Dominate Global Market
- The global market for myeloproliferative disorder can be segmented based on treatment, type, distribution channel, and region
- Based on treatment, the global myeloproliferative disorders market can be categorized into chemotherapy, hormone therapy, stem cell transplant, radiation therapy, and others. The chemotherapy segment is projected to dominate the global market during the forecast period.
- Chemotherapy is widely used as first line of therapy for the treatment of myeloproliferative disorders. Increased adoption of chemotherapy for the treatment and easy availability of this treatment are key factors that are likely to propel the segment during the forecast period
Polycythemia Vera Segment to Lead Global Market
- In terms of type, the global myeloproliferative disorders market can be classified into polycythemia vera, myelofibrosis, eosinophilia, chronic myelogenous leukemia, and chronic neutrophilic leukemia.
- High prevalence and rise incidence rates of polycythemia vera among all other types of myeloproliferative disorders is likely to contribute to the dominant share of the segment during the forecast period
Retail Pharmacies Segment to Lead Global Market
- In terms of distribution channel, the global myeloproliferative disorder market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to dominate the global market during the forecast period.
- Easy availability of myeloproliferative disorder treatment drugs, large number of retail pharmacies, and easy accessibility are estimated to contribute to the dominant share of the segment during the forecast period
North America to Dominate Global Myeloproliferative Disorders Market
- In terms of region, the global myeloproliferative disorders market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America is projected to dominate the global myeloproliferative disorders market during the forecast period. High prevalence and increase in incidence of myeloproliferative disorders, rapid increase in geriatric population, and high per capita healthcare expenditure in the region are key factors that are expected to boost the market in North America during the forecast period.
- The myeloproliferative disorders market in Asia Pacific is likely to expand at a high CAGR during the forecast period due to a rise in the number of people suffering from myeloproliferative disorder, new product development, and increased availability of these treatments in Asia Pacific
- Significant expansion of the healthcare industry, easy access to healthcare facilities, and increase in investments in healthcare by leading players in Asia Pacific are projected to augment the market in the region in the near future
Key Players Operating in Global Myeloproliferative Disorders Market
The global myeloproliferative disorders market is fragmented, with a large number of international and domestic players holding a major share of the global market. Prominent players operating in the global myeloproliferative disorders market include:
- Johnson & Johnson.
- Pfizer, Inc.
- Gilead Sciences, Inc.
- Incyte Corporation
- Bristol- Myers Squibb
- Novartis AG
- Teva Pharmaceuticals
- Bristol-Myers Squibb Company
- Takeda Pharmaceuticals Company Limited
- Zydus Cadila
- Amneal Pharmaceuticals, LLC
- Dr. Reddy's Laboratories Ltd
- Teva Pharmaceutical Industries Ltd
Global Myeloproliferative Disorders Market: Research Scope
Global Myeloproliferative Disorders Market, by Treatment
- Chemotherapy
- Hormone Therapy
- Stem Cell Transplant
- Radiation therapy
- Other
Global Myeloproliferative Disorders Market, by Type
- Polycythemia Vera
- Myelofibrosis
- Eosinophilia
- Chronic Myelogenous Leukemia
- Chronic Neutrophilic Leukemia
Global Myeloproliferative Disorders Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Myeloproliferative Disorders Market, by Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
